)
Anuh Pharma (506260) investor relations material
Anuh Pharma Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Board approved unaudited financial results for the quarter ended 30th June 2026, with review by statutory auditors and audit committee.
Promoter group members withdrew requests for reclassification to public category and will remain promoters.
Revised policy on related party transactions adopted and published on the company website.
Financial highlights
Revenue from operations for Q1 FY27 was ₹19,381.04 lakhs, up from ₹18,647.94 lakhs year-over-year but down from ₹20,211.72 lakhs sequentially.
Net profit after tax for the quarter was ₹1,142.49 lakhs, compared to ₹830.12 lakhs in Q1 FY26 and ₹1,168.14 lakhs in Q4 FY26.
EBITDA for the quarter was ₹1,936.44 lakhs, with an EBITDA margin of 9.99% (up from 7.34% year-over-year).
Basic and diluted EPS for the quarter stood at ₹1.14, compared to ₹0.83 in Q1 FY26.
Outlook and guidance
No explicit forward-looking guidance provided, but continued focus on core bulk drug and chemicals segment.
- FY26 revenue rose 15.66% to ₹776 Cr, driven by exports and regulatory market expansion.506260
Investor presentation28 May 2026 - FY26 revenue rose, but profit and margins declined; bonus shares issued and dividend proposed.506260
Q4 25/2620 May 2026 - Q3 FY26 saw higher revenue, profit, and margins, plus a completed 1:1 bonus share issue.506260
Q3 25/266 Feb 2026 - Q1 FY25 saw lower revenue, profit, and margins, with no material audit issues reported.506260
Q1 24/2527 Nov 2025 - Revenue increased but net profit fell; bonus shares issued and governance policies updated.506260
Q2 25/267 Nov 2025 - Sequential revenue and profit decline offset by year-over-year growth and leadership addition.506260
Q1 25/268 Aug 2025 - Record revenue and export growth, but profit fell; 1:1 bonus and 30% dividend proposed.506260
Q4 24/2517 Jun 2025 - Q2 FY25 delivered strong growth in revenue, profit, and margins, with expanded capacity.506260
Q2 24/2513 Jun 2025 - Revenue and profit declined in Q3 FY25, with EBITDA margin at 9.86%.506260
Q3 24/256 Jun 2025
Next Anuh Pharma earnings date
Next Anuh Pharma earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)